Iosif Kalendarev
Adult Health · New York, NYNPI 1457720963
Payments from drug & device makers
Across 136 payments — averaging $25.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$896
- Blueprint Medicines Corporation$650
- Takeda Pharmaceuticals U.S.A., Inc.$322
- Bristol Myers Squibb$262
- GSK$260
- AbbVie$190
- plus $916 from 14 others
What the payments were for
- Food & beverage$3,497100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 42 | $896 |
| Blueprint Medicines Corporation | 20 | $650 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $322 |
| Bristol Myers Squibb | 10 | $262 |
| GSK | 12 | $260 |
| AbbVie | 2 | $190 |
| Gilead | 7 | $167 |
| Amgen | 7 | $161 |
| Sanofi | 5 | $156 |
| Rigel Pharmaceuticals, Inc. | 5 | $104 |
| Servier Pharmaceuticals LLC | 4 | $69 |
| Azurity Pharmaceuticals, Inc. | 2 | $53 |
| Bayer | 2 | $43 |
| E.r. Squibb & Sons, L.L.C. | 1 | $30 |
| Incyte Corporation | 2 | $29 |
| Daiichi Sankyo Inc. | 1 | $28 |
| Stemline Therapeutics Inc. | 1 | $24 |
| Pfizer | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Merck | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Venclexta$110
How this compares
$3,497 in reported general payments places this provider in the 85th percentile of 3,828 adult health providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 117 | $1,996,621 |
| InqoviDecitabine/Cedazuridine | 26 | $211,443 |
| SprycelDasatinib | 15 | $152,198 |
| Posaconazole | 12 | $8,897 |
| Hydroxyurea | 108 | $1,934 |
| Clobetasol Propionate | 14 | $1,421 |
| Acyclovir | 13 | $87 |
| Allopurinol | 14 | $29 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $29 | $1,996,621117 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel | $30 | $152,19815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,828 adult health providers in New York.
Other adult health in New York
- Marguerite CallahanNew York$1.4M
- Donna CatameroNew York$279K
- Alyson HartyNew York$65K
- Laura GraaflandNew York$51K
- Allysa SaggeseNew York$49K
- Juliet EscalonNew York$46K
- Teshmanie RampersaudNew York$23K
- Jenna WenzelNew York$22K
- Elizabeth SavageNew York$20K
- Libby LevineNew York$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.